Dani Bach
Partner, Life Sciences @ IP Group
Zürich, Switzerland
Dani Bach is an Associate in the life sciences team, having joined the firm in 2007.Dani's areas of interest range from metabolic diseases to virology and prior to joining Index, Dani was conducting research at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human immunodeficiency virus(HIV) and the human immune system.Dani holds a Master in Start-up Business Administration and a PhD in Molecular Biology from the Universitat de Barcelona.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Dani Bach invests in
Stages Dani Bach invests in
Countries Dani Bach invests in
Investment Focus
Industry
- Life Science 1 (33%)
- Biotechnology 1 (33%)
- Manufacturing 1 (33%)
- Pharmaceutical 1 (33%)
Country
- Denmark 1 (33%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vandria
|
Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $10.1M / Series A / Aug 21, 2024 | |
|
Vandria
|
Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $20.6M / Series A / Dec 14, 2023 | |
Cytoki Pharma
|
Cytoki Pharma is a biotechnology company that specializes in developing novel medicines for diseases with a significant unmet medical need with a focus on serious diseases caused by epithelial injury. | $45M / Series A / May 04, 2021 |
Co-Investors
About IP Group
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
IP Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Murphey
Investment Director
|
|||
|
Dani Bach
Partner, Life Sciences
|
|||
Greg Smith
Chief Financial Officer
|
|||
Jamie Vollbracht
Partner, Cleantech
|
|||
Manjari Chandran-Ramesh
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dani Bach invest in?
Dani Bach invests primarily in Life Science, Biotechnology and Manufacturing startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dani Bach last invest?
The most recent investment recorded for Dani Bach closed in Aug 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
